Section Arrow
ATHE.NASDAQ
- Alterity Therapeutics Limited
Quotes are at least 15-min delayed:2026/01/02 12:01 EST
Regular Hours
Last
 3.1723
+0.0923 (+3.00%)
Day High 
3.19 
Prev. Close
3.08 
1-M High
3.635 
Volume 
893 
Bid
3.14
Ask
3.2
Day Low
3.17 
Open
3.19 
1-M Low
2.66 
Market Cap 
56.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.07 
20-SMA 3.19 
50-SMA 3.63 
52-W High
52-W Low 2.5209 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.14/-30.59
Enterprise Value
56.46M
Balance Sheet
Book Value Per Share
1.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
363.78K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.68345-0.89655-56.74%0.58PE
MREOMereo BioPharma Group plc0.474+0.0573+13.75%-- 
SLSSELLAS Life Sciences Group4.145+0.375+9.95%-- 
ASBPAspire Biopharma Holdings Inc.0.1411+0.0092+6.97%-- 
RXRXRecursion Pharmaceuticals4.175+0.085+2.08%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.